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Abstract: 21 
  22 
Elimination of the helminth disease, river blindness, remains challenging due to ivermectin 23 
treatment-associated adverse reactions in loiasis co-infected patients. Here, we address a deficit 24 
in preclinical research tools for filarial translational research by developing Loa loa mouse 25 
infection models. We demonstrate that adult Loa loa worms in subcutaneous tissues, circulating 26 
microfilariae (mf) and presence of filarial biomarkers in sera occur following experimental 27 
infections of lymphopenic mice deficient in interleukin (IL)-2/7 gamma-chain signaling. A 28 
microfilaraemic infection model is also achievable, utilizing immune-competent or -deficient 29 
mice infused with purified Loa mf. Ivermectin but not benzimidazole treatments induce rapid 30 
decline (>90%) in parasitaemias in microfilaraemic mice. We identify up-regulation of 31 
inflammatory markers associated with allergic type-2 immune responses and eosinophilia post-32 
ivermectin treatment. Thus, we provide validation of murine research models to identify loiasis 33 
biomarkers, to counter-screen candidate river blindness cures and to interrogate the inflammatory 34 
etiology of loiasis ivermectin-associated adverse reactions.  35 
  36 
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Introduction  37 
Loiasis (tropical eye worm) is a parasitic helminth disease affecting approximately 13 to 15 38 
million people in forested areas of Central and West Africa 1,2. The disease is transmitted by 39 
blood-feeding Chrysops tabanid flies carrying the causative agent, the filarial worm Loa loa. 40 
Infectious stage L. loa larvae develop into mature adults that migrate within subcutaneous tissues 41 
and the sub-conjunctiva. Mating adult worms release thousands of microfilarial larvae (mf) daily 42 
into the circulation, which are transmitted to the vector upon taking a blood meal 3. Loiasis is the 43 
cause of limb oedema (Calabar swellings) following death of adult worms 4. Chronic infections 44 
cause renal, cardiac, pulmonary and neurological pathologies 3,5,6 linked to excess mortality 7. 45 
Loiasis is also an urgent global health problem as severe and potentially fatal neurological 46 
serious adverse events (SAE) may occur in hypermicrofilaraemic patients (≥30,000 mf/ml blood) 47 
following annual mass drug administration (MDA) of ivermectin (IVM, Mectizan®) for the 48 
treatment of the related filarial disease, onchocerciasis (also known as river blindness) 8. Below 49 
this hypermicrofilaraemic threshold, loiasis individuals remain at significant risk of developing 50 
non-neurological, febrile, temporary debilitating AE following IVM treatment 8,9. The two 51 
filarial infections overlap in Central Africa 10. Social science investigations have identified 52 
perceived risk of loiasis AE as a major factor in persistent non-participation in onchocerciasis 53 
IVM MDA 11. Because IVM MDA has to be delivered annually, at a coverage of 80%, for 54 
periods of 15 years or more, to prevent onchocerciasis transmission 12, and because in loiasis-55 
endemic Central African foci, elimination is not estimated to occur deploying this strategy until 56 
>2045 13, co-infection poses a significant barrier for onchocerciasis elimination programmes. 57 
There is a pressing need to develop new treatment strategies for both loiasis and onchocerciasis 58 
to de-risk AE occurrence in loiasis co-endemic areas and increase participation in river blindness 59 
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elimination campaigns. Strategies include developing a safe drug cure which selectively targets 60 
adult Onchocerca and/or Loa without inducing the rapid Loa microfilaricidal activity of IVM 14 61 
and/or accurately diagnosing loiasis hypermicrofilaraemic individuals at risk of adverse reactions 62 
in a test-and-not-treat with IVM strategy 15. 63 
L. loa naturally infects an endangered species of monkey, the drill (Mandrillus leucophaeus), 64 
endemic to Central Africa. As a surrogate non-human primate model, the life cycle of L. loa can 65 
be maintained via experimental infection of splenectomised baboons 16,17, a model which has 66 
recently been utilised to initiate exploratory pathological studies of IVM-associated neurological 67 
SAE 18,19. This model has also generated adult and mf parasitic stages for a range of ex vivo 68 
studies. However, throughput of the baboon model is severely constraining for anti-filarial drug 69 
research and to identify potential targets for adjunct therapies to prevent IVM SAE. There is 70 
currently no microfilaraemic small animal model of loiasis to use as a refinement to non-human 71 
primates for loiasis translational research whilst simultaneously increasing throughput of 72 
preclinical candidate evaluations. Recently, we identified that attenuated development of juvenile 73 
adult L. loa from infectious inoculates could be generated in selective immune knockout mouse 74 
strains with impaired interleukin-4, IL-5 and IL-13 signalling, providing proof-of-concept that 75 
targeting host adaptive immunity could allow development of human Loa isolates in mice 20. 76 
Further, we have recently established immunodeficient mouse models of related filarial 77 
infections (Brugia and Onchocerca) and implemented them as preclinical macrofilaricidal drug 78 
screens 21-25. 79 
Here we address the current limitation in loiasis preclinical infection models by evaluating 80 
whether lymphopenic, immunodeficient mouse strains are susceptible to patent infection with L. 81 
loa. Further, we explore whether stage-specific, L. loa microfilaraemic mice can be established 82 
5 
 
by blood infusion as a more rapid and facile model system for drug screening including use of 83 
immunocompetent mice for the purposes of exploring inflammatory responses post-IVM 84 
treatment.  85 
86 
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Results  87 
Lymphopenic γc deficient mice are permissive hosts of L. loa 88 
As with other human filarial parasites 21,26, fully permissive L. loa infections cannot establish in 89 
immunocompetent mice due to type-2 associated immunity 26. Developing larvae can survive up 90 
to 2 months post-infection in IL-4Rα-/-/IL-5-/- BALB/c mice but sexual maturity and production 91 
of microfilariae (mf) is not evident in these selective type-2 cytokine deficient animals 20. We 92 
have defined the minimum pre-patent period prior to mf release into blood as 5 months post-93 
infection with human strain L. loa larvae in baboons 18. We therefore investigated the long-term 94 
parasitological success of L. loa infection in a panel of ‘severe-combined’ lymphopenic 95 
immunodeficient mice (Fig. 1). Moderate levels of pre-patent adult L. loa infection were evident 96 
in CB.17 (BALB/c congenic) SCID mice (8/9 mice infected, median % recovery of inoculate = 97 
8.5, Fig. 1A) three months post-infection. Most NOD.SCID mice had cleared infection at the 98 
same time point (2/6 mice infected) suggesting a background strain-dependent susceptibility in 99 
CB.17(BALB/c) vs NOD lymphopenic mice (Fig. 1A). However, deletion of the common IL-2/7 100 
gamma chain (γc) on the NOD.SCID background rendered mice highly susceptible to infection 101 
at the pre-patent adult stage (73% median recovery, 4/4 mice infected, p<0.01 when comparing 102 
NOD.SCIDγc-/- and CB.17 SCID mice, Kruskal-Wallis with Dunn’s post-hoc test, Fig. 1A). We 103 
therefore infected both NOD.SCIDγc-/- mice (commonly known as the NOD.SCID Gamma or 104 
NSG research model) and another compound immunodeficient lymphopenic mouse line on the 105 
BALB/c background, RAG2-/-γc-/-, and compared parasitological success at the time point of 106 
expected patency (5 months) with RAG2-/- γc-sufficient mice. Both compound gamma chain 107 
deficient mouse lines supported survival of adult L. loa at +5 months (NOD.SCIDγc-/- 4/4 mice 108 
infected, 25.5% median recovery, BALB/c RAG2-/-γc-/- 9/9 mice infected, 13% median 109 
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recovery). Conversely, all BALB/c RAG2-/- mice had cleared infection at 5 months (0/10 mice 110 
infected, p<0.0001 when comparing BALB/c RAG2-/-γc-/- to BALB/c RAG2-/- mice, Mann-111 
Whitney test Fig. 1A). At this time point in both compound immunodeficient mouse strains, the 112 
majority of worms were found in the natural tissue niches of Loa adult stages, namely the 113 
subcutaneous and muscle fascia tissues (88% and 78% of total recovered worms in 114 
NOD.SCIDγc-/- and BALB/c RAG2-/-γc-/- mice respectively, n=4-11, Fig. 1B). Mature male and 115 
female worms were recovered, determined by marked difference in lengths (2.9±0.3cm males, vs 116 
4.5±0.3cm females) combined with distinct reproductive morphological characteristics, at a ratio 117 
of between 3:1 and 4:1 females per male (n=4-11, Fig 1C&D, supplementary Fig. 1, 118 
supplementary movie 1). Development of patency was apparent via identification of all 119 
embryonic stages within female uteri (n=4-11, Fig 1D) and release of motile mf ex vivo 120 
(supplementary movie 2). Further, microfilaraemias in BALB/c RAG-/-γc-/- mice 5 months post-121 
infection were apparent (supplementary Fig. 1).  122 
Due to the high reproducible parasitological success of mature L. loa in compound deficient 123 
mice at 5 months post-infection we surgically implanted recovered female and male worms (n=5 124 
per sex) subcutaneously into NOD.SCIDγc-/- or BALB/c RAG2-/- recipient mice. Adult motility 125 
under the skin of recipient mice was frequently evident (supplementary movie 3). One month 126 
post-L. loa adult implantation (6 months development from infectious stage larvae), viable males 127 
and females could be recovered, mainly from subcutaneous tissues, in both mouse strains (3/3 128 
NOD.SCID γc-/- and 5/5 BALB/c RAG2-/- recipients, Fig. 1E, supplementary Fig. 2 and 129 
supplementary movie 4). Further, females were reproductively active one month following 130 
implantation assessed by embryograms ex vivo (supplementary Fig. 2) with 3/3 NOD.SCID γc-/- 131 
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(mean 5980±2240 mf/ml) and 3/5 BALB/c RAG2-/- (mean 874±740 mf/ml) recipients displaying 132 
microfilariaemias by this stage (Fig. 1F).  133 
We tested the utility of the loiasis mouse model to detect biomarkers of living L. loa adult 134 
infection by using two commercially available kits originally developed to specifically detect 135 
Wuchereria bancrofti circulating filarial antigens: the Alera Filarial Test Strip (FTS) and the 136 
TropBio Og4C3 immunoassay. Corroborating reported cross-reactivity of the FTS in recognising 137 
Loa specific secreted antigens 27,28, we identified a strong positive signal in supernatants of both 138 
female and male Loa ex vivo cultures (Fig. 1G and supplementary Fig. 3). When examining sera 139 
from mice infected with L. loa L3, we found that antigenaemia detection with FTS was 140 
reproducibly apparent, dependent on Loa adult infection status but independent of the age of 141 
adult worm infection or microfilaraemic status. Negative serology results were recorded in all 142 
naïve BALB/c RAG2-/- mice (0/3 mice tested) or in BALB/c RAG2-/- mice that had cleared L. loa 143 
at 2-5 months post-infection (0/10 mice FTS positive at each time point). However, all BALB/c 144 
RAG2-/-γc-/- infected mice (10/10 mice, 2 or 5 months post-infection) and all BALB/c RAG2-/- 145 
mice implanted with adult L. loa (5/5 mice, one month post-implantation) were FTS positive 146 
(Fig. 1G and supplementary Fig. 3). Additionally, all infection positive BALB/c RAG2-/-γc-/- 147 
mice (8/8 mice) but not infection negative RAG2-/- mice (0/9 mice) were seropositive for the 148 
distinct filarial adult antigen, Og4C3, five months after experimental infection (p<0.0001, Mann-149 
Whitney test, Fig. 1H). 150 
Loa parasitaemias can establish in mice 151 
Due to the complexity and long lead-time prior to emergence of microfilaraemias in 152 
experimental infections / implantations of immunodeficient mice, we assessed whether infusion 153 
with purified L. loa mf could establish stable parasitaemias as a more facile, stage-specific 154 
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infection model. We also compared performance of immunocompetent versus immunodeficient 155 
mouse lines. After administering intravenous injections of 4x104 L. loa mf through the tail vein, 156 
we observed that wild-type (WT) BALB/c mice had scant and transient microfilaraemias in 157 
peripheral blood up to 4 days post-infusion (mean 48±21 mf/ml, n=8) after which time, no 158 
peripheral circulating mf were detectable (0/8 mice, Fig. 2A). Conversely, L. loa 159 
microfilariaemias were consistently identified in cardiac blood samples at termination, at 7 days 160 
post-infusion, and at higher densities compared with peripheral parasitaemias (mean 1073±503 161 
mf/ml, n=13, Fig. 2B). This indicated that L. loa mf sequestered in the cardiopulmonary 162 
circulation, with only a minor transient peripheral circulation. To test whether splenic secondary 163 
lymphoid tissue or global adaptive immune status exerted a role in limiting L. loa 164 
microfilaraemias in vivo, we compared parasitaemias in WT adult-splenectomised or SCID mice 165 
post infusion with 4x104 L. loa mf. Splenectomy of BALB/c mice allowed a significantly ~2-fold 166 
higher cardiac microfilaraemia at 7dpi versus WT mice (mean 1894±411 mf/mL, p = 0.01, 1-167 
way ANOVA with Dunnett’s post-hoc test, n=13, Fig. 2B) and L. loa mf persisted in peripheral 168 
blood (assessed until 8dpi, Fig. 2A). In CB.17 SCID mice, peripheral parasitaemias were also 169 
consistently detectable (Fig. 2A, n=8). SCID L. loa cardiac microfilaraemias were further 170 
elevated ~4 fold versus WT mice (mean 4562±1098, p = 0.001, 1-way ANOVA with Dunnet’s 171 
post-hoc test, n=15, Fig. 2B), with cardiac parasitaemias consistent and stable over days 2-8 in a 172 
time course experiment (n= 4-8 per time-point, Fig. 2C). Splenectomy of SCID mice did not 173 
further increase yields of microfilaraemias compared with SCID controls (Supplementary Fig. 174 
4).  175 
Loa microfilaraemic mice respond to ivermectin 176 
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We have recently developed and implemented CB.17 SCID mouse models of lymphatic filariasis 177 
and onchocerciasis to evaluate candidate macrofilaricidal activities 21-25. We have also 178 
demonstrated a rapid microfilaricidal response of IVM against circulating Brugia malayi mf in 179 
this research model 21,24. Considering the advantage of a unified ‘pan-filarial’ research model to 180 
interrogate PK/PD relationships of candidate macrofilaricidal drugs, including off-target effects 181 
on Loa mf, and because the highest titres of Loa mf could be achieved in CB.17 SCID mice, we 182 
selected this lymphopenic mouse strain for validation assessments as a loiasis microfilaraemic 183 
counter-screening model. To this end, CB.17 SCID mice were infused with 4x104 L. loa mf and 184 
treated with single-dose IVM or vehicle. IVM mediated a rapid clearance of mf at 2 days post-185 
treatment (92% mean cardiac load reduction versus vehicle, n=4, Fig. 3A). This significantly 186 
increased to a 99% mean reduction versus vehicle at 7 days post-treatment (Student T test, p = 187 
0.013, n=6, Fig. 3A). Peripheral microfilaraemias were completely cleared in 5/6 mice following 188 
treatment at 5dpi (Wilcoxon test, p = 0.031, Fig. 3B). These rapid IVM response dynamics 189 
mirrored the efficacy typically observed in both experimentally infected baboons and human 190 
patients 3,19. The rapid in vivo microfilaricidal activity of IVM was not emulated following short-191 
course oral treatments with either of the candidate macrofilaricide drugs, flubendazole or 192 
oxfendazole 24,29, verifying a lack of off-target efficacy of these benzimidazole chemotypes 193 
against Loa microfilaraemias (Fig. 3C). Contrastingly, IVM efficacy against Loa mf was not 194 
emulated in vitro unless ≥2-day exposures exceeded, by 1000-fold, the typical peak plasma 195 
concentrations in vivo following oral dosing (set at 40ng/ml, supplementary Fig. 5). Similarly, 196 
the more potent macrocyclic lactone, moxidectin, failed to mediate any direct toxicity in vitro 197 
against Loa mf at physiologically relevant levels (supplementary Fig. 5). The in vitro 198 
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insensitivity of Loa mf to macrocyclic lactones was similar to that of the human filaria, Brugia 199 
malayi (supplementary Fig. 5).  200 
Due to the stable parasitaemias evident in both splenectomised and non-splenectomised, immune 201 
competent BALB/c WT mice, we investigated whether IVM microfilaricidal efficacy was 202 
potentiated by host adaptive immune status. When microfilariaemic splenectomised BALB/c 203 
mice were treated with IVM, a similar degree of efficacy was observed compared with SCID 204 
mice (mean 98% reduced microfilaraemia, 7 days post-treatment, p=0.011, Student T test, n=4-5, 205 
Fig. 3D). Immune priming BALB/c mice with subcutaneous inoculations of heat-killed L. loa mf 206 
two-weeks prior to infusion and IVM treatment augmented the IVM treatment response (90% 207 
versus 97% mean reduction in naïve versus immune-challenged mice 7 days post-treatment, n=8 208 
per group, 1-way ANOVA followed by Dunnett’s post-hoc test, p < 0.05 versus p < 0.01 209 
compared to respective vehicle controls, Fig. 3E). Together the data indicates that L. loa 210 
microfilaraemic mice display a typical rapid initial microfilaricidal drug response to IVM over 211 
the course of 7 days post-treatment and efficacy remains intact in SCID or asplenic mice. 212 
However, we provide evidence that prior exposure to Loa mf antigens in immune competent 213 
mice can bolster the rapid efficacy of IVM.  214 
Ivermectin treatment of L. loa induces Type-2 inflammation 215 
Taking advantage of stable parasitaemias over 7 days in WT mice following immune-priming 216 
with heat-killed L. loa mf, we undertook luminex bead-based array analysis of 32 serological 217 
cytokines/chemokines 2-7 days post-IVM treatment and compared responses to untreated 218 
immune-primed mice or immunologically naïve mice that had received matching infusions of 219 
4x104 L. loa mf (n=8 mice per group, Fig. 4). Analytes that were up or down-regulated by more 220 
than 2-fold in immune-primed mouse groups (+/- IVM treatment) versus naïve mice 2 days 221 
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following L. loa infusions were interleukins (IL)-4, 5, 10, 17, interferon gamma (IFNγ), CC-222 
chemokine ligand 11 (CCL11; eotaxin 1) and CXC-chemokine ligand 5 (CXCL5, Fig. 4A). 223 
These analytes were then examined in statistical models to determine significance of fold-224 
changes following immune-priming and IVM treatment. Whilst immune-priming alone induced 225 
significant elevations in circulating interleukins (IL)-4 and IL-5 two days following mf infusions 226 
compared with control mice (mean 3.9±0.8 versus 1.3±0.3 pg/ml, p<0.05 and 67±13.9 pg/ml 227 
versus 13.5±1.5, p<0.01), the magnitude of the IL-4 and IL-5 response was bolstered following 228 
IVM treatment (mean 5.0±0.5 pg/ml, p<0.01 and 151.2±32.5 pg/ml, p<0.001, one way ANOVA 229 
followed by Dunnett’s post-hoc tests, Fig. 4B). Levels of IL-10 and IFNγ were only significantly 230 
elevated in the circulation of immune-primed plus IVM treated microfilaraemic mice compared 231 
with controls (mean 25.5±2.3 versus 13.3±1.1 pg/ml, p<0.05 and 107.0±15.9 versus 45.4±7.5 232 
pg/ml, p<0.01, one way ANOVA followed by Dunnett’s post-hoc tests or Kruskal Wallis test 233 
followed by Dunn’s post-hoc tests respectively, Fig. 4B). Due to augmented efficacy of IVM 234 
after 7 days in immune-primed mice (Fig. 3), we examined the change in inflammatory 235 
responses that were initially up or down regulated post-IVM treatment between D2 and D7 post-236 
treatment. Levels of circulating IL-4 and IL-5 were not altered by D7, whereas IL-10 (mean 237 
16.7±2.9 versus 25.5±2.3 pg/ml, p=0.036, Wilcoxon test), IFNγ (mean 3.7±0.5 versus 238 
107.0±15.9 pg/ml, p=0.008, Wilcoxon test) and IL-17 (mean 3.3±0.8 versus 6.5±1.4 pg/ml, 239 
p=0.039, Wilcoxon test) all significantly had decreased by this time-point post-IVM treatment 240 
(Fig. 4C). Contrastingly, circulating levels of CCL11 had increased on average by >4-fold 241 
between D2 and D7 post-IVM treatment (1993±134.4 versus 450.8±96.5 pg/ml, p=0.008, 242 
Wilcoxon test). Therefore, a type-2 ‘eosinophilic-like’ inflammatory signature was evident in 243 
immunocompetent, antigen-experienced animals 7 days following treatment with IVM. 244 
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Differential white blood cell counts were compared at baseline and D2 in individual mice. Both 245 
monocyte and neutrophil proportions were elevated in the blood of all groups two days after 246 
infusion with 4x104 L. loa mf (3.8±0.6, 9.8±0.8 or 6.2±3.3 mean fold-increases in monocytes, 247 
4.7±0.5, 2.3±0.3 or 3.0±0.5 fold-increases in neutrophils, for untreated, immune-248 
primed+untreated and immune-primed+IVM-treated mice, respectively, n=5 / group, all p<0.05, 249 
paired T test, Fig. 5A). Contrastingly, the eosinophil white blood cell compartment was 250 
significantly elevated 2 days following L. loa infusion in IVM-treated mice only (3.1±0.6 mean 251 
fold-increase, p=0.038, n=5, paired T test, Fig 5A). Tissue granulophilia was then measured 252 
within secondary lymphoid tissue or body cavities of L. loa microfilaraemic mice seven days 253 
after infusion and IVM treatment, compared with untreated controls (Fig. 5B&C). In splenic 254 
tissues, a marked increase in eosinophils were apparent, associated with vasculature of the red 255 
pulp, in IVM-treated, immune-primed mice, compared with controls (2.1±0.1 or 1.8±0.05 mean 256 
fold-change compared with naïve or immune-primed sham treated controls, respectively, n=5, 257 
P<0.001 one way ANOVA with Dunnet’s post-hoc test, Fig. 5B and supplementary figure 6) At 258 
the same time-point, within the peritoneal cavity, a significant, eosinophil-specific granulocyte 259 
exudate was manifest in immune-primed+IVM-treated mice compared with sham treated 260 
controls (1.0±0.15x105 versus 0.32±0.06x105 p<0.05, n=5, one way ANOVA with Dunnet’s 261 
post-hoc test, Fig. 5C and supplementary figure 7). These data indicate IVM treatment responses 262 
culminate in a significant increased myelopoiesis and generalised tissue recruitment of 263 
eosinophil granulocytes in immune-primed L. loa microfilaraemic mice. 264 
 265 
266 
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Discussion  267 
There is renewed investment in developing repurposed, reformulated or new chemical entity 268 
small molecule compounds as macrofilaricides for the priority neglected tropical disease, 269 
onchocerciasis 14,30. A safe, short-course macrofilaricidal agent without significant direct, rapid 270 
toxicity against circulating L. loa mf would be a solution to the spectre of IVM-associated SAE 271 
which is currently contributing to extended global elimination timeframes far beyond the 2025 272 
target in countries where loasis is endemic 13. Whilst we have made recent advances in in vitro 273 
culture screening systems for loiasis, including mf screens 31,32, the standard microfilaricidal 274 
agents: IVM, the related macrocyclic lactone, moxidectin and the piperazine derivative, 275 
diethylcarbamazine (DEC), are inactive in vitro against a range of filarial mf at concentrations 276 
known to induce efficacy in vivo 33,34 (supplementary Fig. 4). Host-directed factors are therefore 277 
speculated to be necessary for IVM efficacy and DEC has been demonstrated to influence host 278 
innate inflammation 33,34. Due to the current limitations in in vivo models of loiasis, our primary 279 
goal was to establish a mouse research model that could accurately evaluate efficacies of 280 
candidate macrofilaricidal drugs on various Loa life cycle stages, namely developing larvae or 281 
adults in subcutaneous tissues and mf in circulation.  282 
Our results demonstrate that development of fecund adult Loa infections in the natural parasitic 283 
niche can be reproducibly achieved in compound immunodeficient, lymphopenic mice lacking 284 
the common gamma chain (γc) cytokine signalling pathway. Contrastingly, following 285 
maturation, adult Loa survival was not dependent on γc signalling, determined by recovery of 286 
mf-producing adult parasites one month post-implantation in γc sufficient SCID mice. A number 287 
of cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) signal via this shared receptor chain 35. 288 
This suggests that facets of the murine innate immune system require one or more of the γc 289 
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cytokine pathways either during haematopoiesis or in response to infection to control loiasis 290 
throughout the L3-L4-L5 development and growth phase. Innate lymphoid cells (ILC) are known 291 
to be important innate immune cells which require γc-dependent cytokine signalling for 292 
haematopoietic development 36. Because specific ILC sub-sets, namely Natural Killer (NK) cells 293 
and ILC2, expand and are associated with immune control of specific nematode infections, 294 
including experimental filarial infections 36-39, further research is required to determine 295 
mechanistic roles for these cell types in the innate control of developing L. loa larvae in 296 
lymphopenic strains of mice.  297 
The establishment of an adult loiasis research model will be of use in preclinical assessments of 298 
candidate macrofilaricides targeting Loa and the ability to implant defined burdens of Loa male 299 
and females prior to drug testing will aid accuracy of readouts. The model is thus ready to test 300 
treatment responses to ‘reference’ macrofilaricides, such as flubendazole, and to scrutinise 301 
whether dose alterations of human registered drugs (e.g. albendazole) or re-purposing the 302 
veterinary agents: emodepside or oxfendazole, can mediate substantial and selective 303 
macrofilaricidal activities against L. loa in vivo. Because Loa circulating glycoproteins could be 304 
readily detected by commercial filarial immunodiagnostic tests in both pre-fecund and fecund 305 
Loa infected mice, this research model could also be readily applied in the preclinical discovery 306 
of Loa adult biomarkers and evaluation of specific Onchocerca candidate biomarkers currently 307 
in development as potential point-of-care diagnostics 40,41. Beyond translational research, the 308 
murine model will be of benefit to basic parasitological researchers by facilitating a convenient, 309 
abundant source of all mammalian life cycle stages of Loa parasites for molecular and genomic 310 
studies as an alternative to non-human primate (NHP) usage. 311 
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The more facile approach of infusing purified mf directly into venous blood generated similar 312 
levels of parasitaemias as observed post-adult implantations, in both immunodeficient and 313 
immunocompetent mice. No model supported ‘hypermicrofilariaemias’ in the peripheral 314 
circulation but displayed between 102 and 104 mf/ml rapidly sequestering in the cardiopulmonary 315 
circulation following 4x104 mf infusions. This may reflect the anatomical size differences 316 
between murine and human microvasculature whereby Loa mf are hindered when traversing 317 
murine capillary beds. Alternatively, or in addition, because Loa exhibit a diurnal periodicity in 318 
humans 42, physiological cues for oscillatory peripheral circulatory migration versus 319 
cardiopulmonary sequestration may vary between mice and humans. Similarly, human sub-320 
period strain B. malayi also demonstrate a tropism for cardiopulmonary circulation when infused 321 
into mice 21,24. Adult splenectomy of WT mice improved parasitaemia yields yet SCID mice 322 
(without splenectomies) supported the highest parasitaemias and splenectomies of SCID mice 323 
did not further elevate microfilaraemias. This suggests that any splenic mediated clearance of mf 324 
is part of an adaptive immune-dependent process. 325 
Consequently, we were able to validate that rapid microfilaricidal activity of IVM against blood-326 
borne Loa mf could be modelled in both immunodeficient and -competent mouse strains and 327 
subsequently explored the dependence of adaptive immune processes in IVM-mediated 328 
microfilaricidal efficacy. Our data demonstrates that typical, rapid, >90% clearance of mf from 329 
both cardiopulmonary and peripheral blood by either oral or parenteral, single dose IVM does 330 
not require adaptive immunity. This was in marked contrast to a lack of in vitro activity of IVM 331 
or the related, more potent macrocyclic lactone, moxidectin, at physiologically relevant 332 
exposures of drug. However, we determined that antigen-experienced, immunocompetent mice 333 
were subtly more sensitive to the effects of IVM clearance of Loa mf. Our data is consistent with 334 
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previous findings that IVM can mediate high microfilaricidal activities against Brugia or 335 
Onchocerca mf in lymphopenic mouse strains 21,24,43 and we conclude that whilst adaptive 336 
immunity is not a necessary host-directed component of the IVM microfilaricidal mode of 337 
action, variation in adaptive immune potential may influence magnitude of treatment response 338 
post-IVM treatment of loaisis individuals. Because we have previously developed, validated and 339 
implemented a CB.17 SCID mouse model to test macrofilaricidal activities against Brugia and 340 
Onchocerca adult filariae 21-25, the CB.17 SCID Loa microfilaraemic mouse model is ideal to be 341 
implemented as a corresponding counter-screen to scrutinise for ‘off-target’ rapid, direct 342 
microfilaricidal activities. By using the same inbred strain, significant discrepancies in drug 343 
exposures between macrofilaricide and microfilaricidal efficacy tests should be avoided. We 344 
initially implemented the screen to test for ‘off-target’ activities of a veterinary anthelmintic, 345 
oxfendazole, which has undergone phase I trials as a repurposed treatment for human 346 
helminthiases (ClinicalTrials.gov NCT03035760) or the oral reformulation of flubendazole and 347 
determined that both benzimidazole anthelmintic chemotypes have no rapid IVM-like activity at 348 
dosages known to mediate macrofilaridal activity in preclinical mouse models 24,29. 349 
Beyond the immediate translational research priorities of new drugs and diagnostics for filarial 350 
diseases in loiasis co-morbidities, the aetiology of loiasis adverse reactions needs to be more 351 
thoroughly understood. Determining the pathophysiology of Loa AE is critical if effective 352 
adjunct therapies are to be deployed during IVM administration to at-risk groups to reduce the 353 
risk of AE and increase population adherence to MDA. Adjunct therapy is foreseeable as part of 354 
a ‘test-and-not-treat’ strategy using the recently developed Loa CellScope point-of-care device 355 
that can discern low-moderate, high or very high microfilaraemias, as a traffic light warning 356 
system 44,45. We therefore exploited the susceptibility of WT mice to Loa microfilaraemias post-357 
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immune priming to initially explore the systemic inflammatory responses induced by rapid IVM-358 
mediated clearance of mf from the blood. We chose to examine these responses in ‘antigen 359 
experienced’ animals to more align with chronically infected human populations. Whilst initially 360 
both type-1 (IFNγ) type-2 (IL-4, IL-5, CCL11) and regulatory type (IL-10) inflammatory 361 
mediators were upregulated post-IVM treatment, by seven days a switch to a predominant type-2 362 
inflammatory signature was apparent, characterised by maintenance of IL-4 and IL-5, 363 
downregulation of IFNγ and IL-10 and significant increases of the eosinophil chemotactic factor 364 
CCL11. We have further characterized an augmented eosinophilia in peripheral circulation, in 365 
secondary lymphoid tissue and in the peritoneal cavity of antigen experienced, microfilaraemic 366 
mice as a consequence of IVM treatment. This suggests a predominance of allergic immune 367 
responses are induced post-IVM, probably induced by liberation of mf somatic antigens, which 368 
may be targetable via anti-allergy / asthma type therapeutics. Certainly, eosinophil-containing 369 
micro-lesions have been identified in brain capillaries post-IVM treatment of baboons 19 and 370 
both increased IL-5 and eosinophilia is evident in loiasis patients post-IVM or DEC treatment 46 371 
corroborating that eosinophilic responses in the research model emulate clinical inflammation 372 
post-treatment. Considering the availability of a full spectrum of murine biological research 373 
reagents and transgenic animals, the research model now offers a powerful new approach to 374 
dissect inflammatory AE, acute tissue pathologies and evaluate therapeutic targeting of host 375 
inflammation post-IVM treatment. 376 
Current limitations of both research models include the proximity to a source of Loa L3, 377 
necessary continued usage of experimentally infected baboons to provide mf and restraints on 378 
the numbers of L3 that can be acquired via trapping of wild flies. This means that loiasis mouse 379 
models are not currently available outside of the endemic region of Central Africa. However, we 380 
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are investigating approaches to experimentally infect Chrysops with purified mf to increase 381 
throughput of infectious stage larvae. Preliminary ongoing experiments support that micro-382 
injections of L. loa mf into wild-caught Chrysops can yield infectious stage larvae which develop 383 
into juvenile adult worms in mice. Following ethical permissions, we intend to evaluate whether 384 
purifications of mf from hypermicrofilaraemic human donors can be used to obviate the 385 
requirements for NHP experimentation and further increase throughput. Such experiments may 386 
also define the extent of diurnal periodic migrations displayed by blood borne mf within 387 
microfilaraemic mouse models. Certainly, preliminary studies in splenectomised baboons 388 
indicates diurnal fluctuations of human strain L .loa are apparent. Further, we are validating 389 
whether using cryopreservations of mf or L3 can extend the accessibility of the models to non-390 
endemic country research laboratories. Another present limitation of the infusion model to study 391 
treatment-associated pathology is that overt neurological-type AE have not yet been observed 392 
post-IVM delivery. However, we are currently investigating the fate of mf post-treatment, 393 
including tropism and histopathological consequences in brain-associated vasculature, and 394 
whether increasing inoculates of mf in SCID or WT mice will lead to evidence of neurological 395 
dysfunction post-treatment. 396 
For basic biology research of loiasis and other filariae, establishing mouse models will be a 397 
powerful new tool to interrogate important host-parasitological interactions such as how 398 
periodicity is influenced by host factors and dissecting stage-specific immune responses to 399 
larvae, adults and mf. Similarly, by establishing microinjections of mf derived from mice into 400 
Chrysops vectors, detailed, timed infection-courses could reveal new biological insights of the 401 
parasite-vector biology.  402 
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In conclusion, we have developed novel small animal models of loiasis sufficiently robust for 403 
immediate implementation in preclinical research to accelerate development of novel drugs, 404 
therapeutics and diagnostics for filariasis elimination in Central Africa. 405 
406 
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 Methods 407 
 408 
Animals 409 
BALB/c, BALB/c RAG2-/-γc-/-, CB.17 SCID, NOD.SCID and NOD.SCIDγc-/- (NSG) mice of 5-410 
6 weeks of age were purchased from Charles River Europe and BALB/c RAG2-/- mice were 411 
kindly provided by Prof Andrew McKenzie (MRC Laboratory of Molecular Biology, Cambridge 412 
University, United Kingdom) and by Prof. Dr. Antonius Rolink (Developmental and Molecular 413 
Immunology Department of Biomedicine, University of Basel, Switzerland). Mice were shipped 414 
in filter topped boxes to Research Foundation for Tropical Diseases and the Environment 415 
(REFOTDE), Buea, Cameroon. All mice were reared in REFOTDE in a 12:12 light:dark cycle, 416 
maintained in individually ventilated caging (IVC) with HEPA filtered air system (Tecniplast) 417 
with ad libitum provision of standard irradiated rodent chow and bottled mineral water. All mice 418 
used for the experiments were infected in the laboratory of REFOTDE. All animal procedures 419 
received ethical approval by the Animal Care Committee at REFOTDE and undertaken in 420 
accordance with UK regulatory standards. 421 
L. loa microfilariae (mf) were obtained from splenectomised infected baboons (Papio anubis) 422 
that were kept in captivity and infected with the L. loa human strain 17,32,47. The acquisition, care 423 
and ethical concerns on the use of baboons as donors of mf have been previously documented 424 
18,20. Ethical and administrative approvals for the use of baboons in this study were obtained from 425 
the Ministry of Scientific Research and Innovation of Cameroon (Research permit 426 
#028/MINRESI/B00/C00/C10/C12) and the Animal Care Committee at REFOTDE. Procedures 427 
adhered to the NIH Guide for the Care and Use of Laboratory Animals. Authors have complied 428 
with all relevant ethical regulations for animal testing and research. 429 
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 430 
Parasites 431 
L. loa mf were extracted from the blood using a Percoll® gradient centrifugation processing 432 
18,32,48 with a discontinuous gradient of 65%, 50% and 40% iso-osmotic Percoll®. Two ml of 433 
whole blood collected on the same day were loaded on the top of the gradient and centrifuged at 434 
400G for 20min; the layer containing mf was carefully removed and filtered gently through a 435 
5µm pore-size cellulose filter and mf were then transferred into a Petri dish containing culture 436 
medium (10% fetal calf serum -FCS- supplemented Dulbecco's Modified Eagle's Medium -437 
DMEM-) and incubated 5 min / 37oC to release mf. Suspensions were then centrifuged to 438 
concentrate mf. Unless stated otherwise, 4x104 mf in 150µl RPMI were loaded in 26G 1ml 439 
insulin syringes and maintained at 37oC until intravenously injected in the tail vein of the mice.  440 
L. loa L3 infective stages were derived from wild caught Chrysops silacea via baited traps in a 441 
known hyperendemic area. Flies were dissected to allow release of any L. loa L3 infective 442 
stages. Infective doses of 100 to 200 L3 per 200µL medium (DMEM + 10% FCS) were loaded 443 
in 25G 1mL syringes and subcutaneously injected into mice. 444 
L. Loa adult worms were obtained from CB.17 SCID, NOD.SCID, NOD.SCIDγc-/- (NSG) and 445 
BALB/c RAG2-/-γc-/- mice that were infected with L. loa L3 and culled either at 3 or 5 months’ 446 
post-infection. Worms were then either sub-cutaneously re-implanted into new recipient mice, 447 
fixed for histology or utilised in embryogram assays. 448 
 449 
Experimental infections and drug treatments 450 
Mice were infected with either 100 or 200 L.loa L3 via sub-cutaneous injection or with 5 male / 451 
5 female L. loa adult worms via surgical sub-cutaneous implantation or 4x104 L. loa mf via a tail 452 
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vein infusion. In the case of surgical implantation, mice were placed under anesthesia using 453 
intra-peritoneal injections of ketamine (Ketaset, 70mg/kg) and medetomidine (Domitor, 454 
0.8mg/kg) with surgery, post-operative monitoring and recovery 21. L. loa adults were washed in 455 
several changes of medium (DMEM + 10% FCS) and groups of 5 females and 5 males were 456 
surgically implanted under the dorsal back skin behind the neck. 457 
For immune priming experiments, aliquots of 3x104 L. loa mf were killed through 3 cycles of 458 
10min at +50 oC followed by 10min at -50 oC incubations. Aliquots of 3x104 dead L. loa mf were 459 
sub-cutaneously injected to each mouse. Mice were challenged with 4x104 L. loa mf 14 days 460 
post-immune priming. 461 
Mice were treated orally with ivermectin (Sigma-Aldrich) at 1mg/kg in water, with ivermectin 462 
sub-cutaneous injections at 5mg/kg in water, orally with flubendazole (Janssen BEND 463 
formulation, a gift from Dr B. Baeton, Jansssen Pharmaceutica, Beerse, Belgium) at 40mg/kg 464 
24,29, or orally with oxfendazole (Dolthene formulation, Vetsend) at 25mg/kg in corn oil. 465 
Mice were euthanized using CO2 rising concentrations. Post-mortem, blood was collected by 466 
cardiac puncture using either a heparinized 25G needle and 1mL syringe for plasma collection or 467 
a non-heparinized syringe and needle for thick smears and serum collection followed by 468 
systematic dissection for adult parasite recovery.  469 
 470 
Peripheral and cardiopulmonary microfilaraemias 471 
Infected mice were checked for the presence of mf in blood by thick smear and subsequent 472 
Giemsa staining. Briefly, blood was collected from the tail vein (2x20µL) or from the heart 473 
(2x50µL) at necropsy using a 25G 1mL syringe, transferred onto glass slides and then processed 474 
for thick smears through a scratch method. Air-dried smears were incubated in distilled water for 475 
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4min to lyse erythrocytes, fixed in methanol for 1min and finally stained with 40% Giemsa for 476 
40min then washed in distilled water until clear. Duplicate slides were counted twice with 477 
microscope operators blinded to treatment group. 478 
 479 
Serological studies 480 
Mouse sera or plasma were tested for filarial antigen detection using 2 kits commercially 481 
available for the detection of Wuchereria bancrofti antigens: the filariasis test strip (FTS, Alere, 482 
Abbott UK) and the Og4C3 filariasis antigen ELISA (Tropbio, Cellabs, UK), both as per 483 
manufacturer’s instructions. A volume of 70μL fresh serum was used immunochromatographic 484 
detection with the FTS per test strip with reading taken within minutes after sample application.  485 
Plasma cytokines/chemokines levels in mouse plasma were determined using a 32-analyte 486 
multiplex cytokine immunoassay based on xMAP technology (MCYTMAG-70K-PX32 kit, 487 
Millipore) as per manufacturer’s instructions and samples were analyzed on a LX100TM 488 
multiplexing instrument (Luminex). Analytes included were: eotaxin, G-CSF, GM-CSF, M-CSF, 489 
gamma interferon (IFN-γ), TNF-α, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, 490 
IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, CCL2, CCL3, CCL4, CCL5, CXCL1, 491 
CXCL2, CXCL5, CXCL9, leukemia inhibitory factor (LIF), and vascular endothelial growth 492 
factor (VEGF).  493 
 494 
Flow cytometry 495 
Mouse peritoneal cells were collected via a peritoneal cavity wash with 10mL PBS-5% FCS. 496 
Single cell suspensions were prepared in FACS buffer (PBS+0.5%BSA+2mMEDTA). Fc 497 
receptors were blocked with αCD16/32 (1/40 dilution, ref: 14-0161-82, eBioscience) prior to the 498 
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application of the following cocktail: viability dye eFluor450 (ref: 65-0863-14, eBioscience), 499 
anti-mouse SiglecF-APC (dilution 1/40, clone S17007L, ref: 155508, Biolegend) and anti-mouse 500 
Ly6G-FITC (dilution 1/40, clone RB6-8C5, ref: 11-5931-82, eBioscience) or their matched iso- 501 
type controls using a fluorescence-minus-one method. Samples were fixed in FACS buffer 502 
containing 0.5% PFA and shipped at 4°C to UK. All multi-labelled cell samples were 503 
subsequently acquired using a BD LSR II flow cytometer (BD Bioscience) and analysed on 504 
FlowJo Software (Supplementary Figure 7). OneComp eBeads (eBioscience) were used to 505 
optimise antibody staining panels and apply compensation. For compensation controls, optimal 506 
PMT voltages for the positive signal to be detected were set within 10^4 and 10^5 whereas 507 
negative signal was set to below 10^2.  508 
 509 
Differential blood count thin smears 510 
Thin smears were performed on peripheral blood collected from the mouse tail vein and were 511 
stained in May-Grünwald (Sigma) for 5 min then in 40% Giemsa for 30min. Leukocytes 512 
numeration was performed under a microscope counting 200 leucocytes. Operators were blinded 513 
to mouse groups. 514 
 515 
Histological studies 516 
Female and male worms were processed as whole mounts for anatomical observation. Worms 517 
were fixed in hot 70% ethanol then mounted on a glass slide within drops of glycerol. Samples 518 
were allowed an overnight incubation a room temperature to fully perfuse the worms with 519 
glycerol and worms were analyzed on an Olympus BX60 microscope. 520 
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Spleens from mice were collected at readout and fixed in 10% PFA for 24h then transferred in 521 
70% ethanol and subsequently embedded in paraffin. Paraffin sections (5 μm) were stained with 522 
hematoxylin-eosin (H&E, VWR) for the detection of eosinophils. Images were acquired using 523 
the digital slide scanner HPF-NanoZoomer RS2.0 (Hamamatsu) coupled to a high definition 3-524 
CCD digital camera of the PHIC immunohistochemistry platform (Institut Paris-Saclay 525 
d’Innovation Thérapeutique, France). Eosinophils were counted from 10 quadrants of 526 
120µmx200µm per splenic zone per mouse. Operator was blinded to mouse group. 527 
 528 
Statistical analysis 529 
Data was first checked for normality, using D’Agostino & Pearson omnibus Shapiro-Wilk 530 
normality tests before or post log10 transformation of raw data. If raw or transformed data passed 531 
both tests, two-tailed parametric Student’s T-Test (two variables) or one-way ANOVA with 532 
Dunnett’s post-hoc tests (>two variables) were used. If the data failed to pass normality testing, 533 
two-tailed Mann-Whitney (two groups) or Kruskal-Wallis with Dunn’s post-hoc tests (>two 534 
variables) were used. Significant changes in paired data were tested by T-tests or Wilcoxon tests. 535 
All tests were performed in GraphPad Prism software at a significance level of 5% and 536 
significance is indicated P<0.05* P<0.01** P<0.001***. Heatmap analysis was undertaken in 537 
Excel using conditional formatting with -10 fold change being color-coded as blue and +10 fold 538 
change being reported as red. 539 
  540 
27 
 
Data availability 541 
 542 
The data that support the findings of this study are available from the corresponding author upon 543 
reasonable request.   544 
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Figure legends:  696 
 697 
Fig. 1: Chronic L. loa infection can be achieved in lymphopenic mice deficient in the 698 
common gamma chain. (A) L. loa adult worm burdens at 3 and 5 months post-infection in 699 
lymphopenic mouse strains with or without compound IL-2/7 gamma chain (γc) deficiency (3 700 
months: CB.17 SCID n=11, NOD.SCID n=6, NOD.SCIDγc-/- n=4. 5 months: NOD.SCIDγc-/- 701 
n=4, BALB/c RAG2-/ n=10, BALB/c RAG2-/-γc-/- n=9 mice). Plotted is % adult recovery of 702 
infectious inoculum for individual mice and median levels. (B) tissue distributions of adult L. loa 703 
in NOD.SCIDγc-/- (n=4) or BALB/c RAG2-/-γc-/- (n=9) mice, 5 months post-infection. Plotted is 704 
mean % of total yields per tissue site. (C) sex ratio of adult L. loa in NOD.SCIDγc-/- (n=4) or 705 
BALB/c RAG2-/-γc-/- (n=9) mice, 5 months post-infection. Plotted is % adult recovery of 706 
infectious inoculum for individual mice and median levels. (D) representative photomicrographs 707 
of L. loa female (upper left and middle pictures) and male (upper right) worms recovered from 708 
an infected BALB/c Rag2-/-γc-/- mouse at 5 months post-infection. u: uterus, p: uterine pore, c: 709 
coiled microfilariae, m: microfilariae, s: spicule. Scale bar = 1cm. The micrograph at the bottom 710 
represents an hematoxylin/Eosin staining of a paraffin embedded section of a L. loa female 711 
worm recovered 1 month post-implant in a BALB/c Rag2-/- mouse. u: uterus, e: embryos, smf: 712 
stretched microfilariae, cmf: coiled microfilariae. Scale bar: 0.2mm. (E) adult worm yield 1 713 
month post-adult implants in NOD.SCIDγc-/- and BALB/c Rag2-/- mice, n=3-5. (F) microfilariae 714 
production 1 month post- adult implants in NOD.SCIDγc-/- (n=3) or BALB/c Rag2-/- mice (n=5). 715 
(G) summary table of filariasis test strips (FTS) outcome when testing worms culture 716 
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supernatants after overnight incubation at 37°C (n=3 cultures) and mice sera from selected 717 
infection conditions, (n=3 naive mice, n=5 BALB/c Rag2-/- mice 1 month post-implantation, 718 
n=10 all other mouse infections). (H) Og4c3 quantitative circulating antigen at 5 months post-719 
infection, (n=10 BALB/c Rag2-/- or n=9 BALB/c RAG2-/-γc-/-mice). Plotted is individual data and 720 
median levels. Significant differences between strains are determined by two-tailed Mann-721 
Whitney (two groups) or Kruskal-Wallis with Dunn’s post-hoc tests (>two variables). 722 
Significance is indicated *P<0.05, **P<0.01, ****P<0.0001. 723 
 724 
Fig. 2: L. loa microfilariaemias can be established in immunocompetent and 725 
immunocompromised mice. (A) time-course of peripheral microfilariaemias in CB.17 SCID 726 
n=12, BALB/c WT adult splenectomised (spl.), n=14 or BALB/c WT, n=8 mice, 2-8 days 727 
following infusion with 40,000 purified L. loa mf. Plotted are mean±SEM of time course data. 728 
(B) level of L. loa microfilariaemia in cardiac blood in CB.17 SCID, n=13, BALB/c WT spl., 729 
n=13 or BALB/c WT, n=15 mice 7 days post-infusion with 40,000 purified L. loa mf. Plotted are 730 
individual data and means±SEM. (C) level of L. loa microfilariaemia in cardiac blood in groups 731 
of n=4-8 CB.17 SCID microfilaraemic mice, evaluated at between 2-8 days following infusion 732 
with 40,000 purified L. loa mf. Plotted are individual data and means±SEM. All data is derived 733 
from a single individual experiment (C) or pooled from two experiments (A-B). Significant 734 
differences are determined by 1 way ANOVA with Dunnett‘s post-hoc tests for >2 groups of log 735 
transformed data (A,B) or Kruskal-Wallis with Dunn‘s post-hoc tests, per time point (C). 736 
Significance is indicated *P<0.05, **P<0.01, ***P<0.0001, nd: not different. 737 
 738 
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Fig. 3: Ivermectin mediates rapid microfilaricidal activity in L. loa microfilaraemic mice. 739 
(A) level of microfilaricidal efficacy in CB.17 SCID mice, 2 days (n=4) or 7 days (n=6) post-740 
single oral treatment with ivermectin (IVM), expressed as a % reduction in cardiac blood L. loa 741 
microfilariaemias from mean vehicle control levels. Plotted are individual data and means±SEM. 742 
(B) change in peripheral L. loa in CB.17 SCID microfilaraemic mice (n=6), 5 days following 743 
vehicle or single IVM injection. Plotted are individual data. (C) differential microfilaricidal 744 
efficacy in microfilaraemic CB.17 SCID mice of oral (n=8) and parenteral (sub-cutaneous; s.c, 745 
n=4) IVM dosing compared with macrofilaricidal benzimidazole drugs, flubendazole (FBZ, 746 
single dose, n=5) or oxfendazole (OX-BZ, daily for 5 days, n=5). Plotted are individual data and 747 
means±SEM. (D) microfilaricidal efficacy of parenteral IVM dosing (n=5) versus vehicle (n=4) 748 
in microfilaraemic splenectomised BALB/c mice. Plotted are individual data and means±SEM. 749 
(E) microfilaricidal efficacy of parenteral IVM dosing in microfilaraemic BALB/c mice (n=8 per 750 
group) ± prior immune priming (2 weeks before treatment) with s.c. inoculations of 104 heat-751 
killed L. loa mf or in vehicle controls (n=7). Plotted are individual data and means±SEM. Data is 752 
pooled or representative of two individual experiments. Significant differences are determined by 753 
Student T test for two groups or 1 way ANOVA with Dunnett‘s post-hoc tests for >2 groups of 754 
log10 transformed data. Significant changes in paired data is tested by Wilcoxon Tests. 755 
Significance is indicated *P<0.05, **P<0.01, ***P<0.0001. 756 
 757 
Fig. 4: Type-2 systemic inflammation is evident post-ivermectin treatment of L. loa 758 
microfilaraemic mice. (A) Plasma cytokines/chemokine changes 2 days post-infusion with 759 
40,000 purified L. loa mf into BALB/c mice with prior immune-priming via s.c. inoculations of 760 
1x104 heat-killed L. loa mf and either IVM 5mg/kg (n=8) or sham-treatment s.c. at the point of 761 
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infusion (n=8). Plotted is median fold-change compared with non-immune primed, sham-treated 762 
L. loa microfilaraemic controls (n=7). Colour scale depicts <-10 (dark blue) to >10 (dark red) 763 
fold difference with white being 1 (i.e. no difference). (B) cytokines/chemokines with ≥2-fold 764 
increase or decrease following immune-priming (n=8) and/or immune-priming+IVM treatments 765 
(n=8) compared with non-immune primed, sham-treated L. loa microfilaraemic controls (n=7). 766 
Data plotted are individual data and means±SEM. Significant differences are determined by 1-767 
way ANOVA with Dunnett’s post-hoc tests of either raw or log-transformed data (IL-4,5,10, 768 
CCL11, CXCL5) or Kruskal-Wallis tests with Dunn‘s post-hoc tests (IFNg, IL-17). (C) changes 769 
in circulating cytokine/chemokine levels between 2 and 7 days post-IVM treatment in immune-770 
primed L. loa microfilaraemic mice (n=8). Plotted are individual data. Significant differences are 771 
determined by paired Student T tests (IL-4, -5, -10) or Wilcoxon tests (IFNg, CCL11, CXCL5, 772 
IL-17). All data is pooled from two individual experiments. Significance is indicated *P<0.05, 773 
**P<0.01. ***P<0.001. 774 
 775 
Figure 5: Ivermectin treatment induces eosinophilia in L. loa microfilaraemic mice. (A) 776 
differential white blood cell counts determined by blood thin smear and MGG staining at 777 
baseline or 2 days post-infusion with 40,000 purified L. loa mf into BALB/c mice ± prior 778 
immune-priming with s.c. inoculations of 1x104 heat-killed L. loa mf and sham or IVM 5mg/kg 779 
treatment s.c. at the point of infusion (n=5 mice per group). Proportions of basophils, 780 
eosinophils, monocytes and neutrophils were enumerated per 200 leucocytes per slide. Data 781 
plotted are specific cell proportions of total leukocytes (%) of individual mice and mean±SEM. 782 
(B) eosinophil counts in the red pulp, vasculature, white pulp marginal zones and germinal 783 
centres in sections of spleen 7 days post-infusion with 40,000 purified L. loa mf into BALB/c 784 
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mice ± prior immune-priming with s.c. inoculations of 1x104 heat-killed L. loa mf and sham or 785 
IVM 5mg/kg treatment s.c. at the point of infusion (n=3 mice per group). Plotted is mean counts 786 
for 10 quadrants of 120µmx200µm per splenic zone per mouse, and mean±SEM per group. (C) 787 
eosinophil and neutrophil enumerations within peritoneal exudate cells acquired by flow 788 
cytometry, 7 days post-infusion with 40,000 purified L. loa mf into BALB/c mice ± prior 789 
immune-priming with s.c. inoculations of 1x104 heat-killed L. loa mf and sham or IVM 5mg/kg 790 
treatment s.c. at the point of infusion (n=5 mice per group except sham group, n=6). Plotted is 791 
individual data and mean±SEM. Significant changes in paired data is tested by T-test (A). 792 
Significant differences for 3 independent groups are determined by 1 way ANOVA with 793 
Dunnett‘s post-hoc tests (B,C). Significance is indicated *P<0.05, **P<0.01, ***P<0.001. 794 
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